Global tuberculosis incidence has declined marginally over the past decade, and
tuberculosis remains out of control in several parts of the world including Africa and Asia …

Clinical microbiology has long relied on growing bacteria in culture to determine
antimicrobial susceptibility profiles, but the use of whole-genome sequencing for antibiotic …

A clear understanding of the genetic basis of antibiotic resistance in Mycobacterium
tuberculosis is required to accelerate the development of rapid drug susceptibility testing …

Background Accurate and rapid detection of tuberculosis (TB) and drug resistance are
critical for improving patient care and decreasing the spread of TB. Xpert® MTB/RIF assay …

The rise of antibiotic-resistant bacteria has led to an urgent need for rapid detection of drug
resistance in clinical samples, and improvements in global surveillance. Here we show how …

Mycobacterium tuberculosis drug resistance (DR) challenges effective tuberculosis disease
control. Current molecular tests examine limited numbers of mutations, and although whole …

The emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR)
tuberculosis (TB) substantially challenges TB control, especially in the European Region of …

Drug-resistant tuberculosis is a substantial health-care concern worldwide. Despite culture-
based methods being considered the gold standard for drug susceptibility testing, molecular …

Drug-resistance testing, or antimicrobial susceptibility testing (AST), is mandatory for
Mycobacterium tuberculosis in cases of failure on standard therapy. We reviewed the …

Background Xpert MTB/RIF and Xpert MTB/RIF Ultra (Xpert Ultra) are World Health
Organization (WHO)‐recommended rapid tests that simultaneously detect tuberculosis and …